Výsledky vyhledávání - "Marek Peterka"

Akademický článek

The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021

Publikováno v: Biomedical Papers, Vol 168, Iss 3, Pp 262-270 (2024)

Aims. Multiple sclerosis treatment strategies are changing in the Czech Republic. According to data from 2013-2021, the proportion of patients starting high-efficacy disease-modifying therapies is increasing. In this survey, we describe the actual da

Externí odkaz: https://doaj.org/article/031942c91d96488a818590beaafcebd7

Zobrazit plný text záznamu

Akademický článek

Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registry

Publikováno v: Journal of Central Nervous System Disease, Vol 16 (2024)

Background Cladribine, a selective immune reconstitution therapy, is approved for the treatment of adult patients with highly active multiple sclerosis (MS). Objectives Provide experience with cladribine therapy in a real-world setting. Methods This

Externí odkaz: https://doaj.org/article/184f4c6999bb4bada8b072f3e0cb99d2

Zobrazit plný text záznamu

Akademický článek

Quantiferon Monitor Testing Sheds Light on Immune System Disparities between Multiple Sclerosis Patients and Healthy Individuals

Autor: Ilona Součková, Ondřej Souček, Jan Krejsek, Oldřich Vyšata, David Matyáš, Marek Peterka, Michal Novotný, Pavel Kunc, Zbyšek Pavelek

Publikováno v: International Journal of Molecular Sciences, Vol 25, Iss 4, p 2179 (2024)

The aim of this study was to conduct QuantiFERON Monitor (QFM) testing in patients with multiple sclerosis (MS), which is used to monitor the state of the immune system through the non-specific stimulation of leukocytes followed by determining the le

Externí odkaz: https://doaj.org/article/dd95da90c19c46ac82468c8c011e3116

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor

Autor: Zbysek Pavelek, Ondrej Soucek, Jan Krejsek, Ilona Sejkorova, Oldrich Vysata, Blanka Klimová, Francesco Angelucci, Pavel Stourac, Martin Valis, Marek Peterka, Lukáš Sobisek, Michal Novotny

Publikováno v: Journal of Immunology Research, Vol 2023 (2023)

Background. The QuantiFERON®-Monitor (QFM) is an assay that measures interferon-γ production and was developed to provide an objective marker of complex immune response. In this study, we evaluated the use of the QFM test in patients with two forms

Externí odkaz: https://doaj.org/article/681588e3d4a84d559d0b5dd4548066b2

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry

Autor: Martin Vališ, Zbyšek Pavelek, Michal Novotný, Blanka Klímová, Jana Šarláková, Simona Halúsková, Marek Peterka, Ivana Štětkárová, Pavel Štourač, Jan Mareš, Pavel Hradílek, Radek Ampapa, Marta Vachová, Eva Recmanová, Eva Meluzínová

Publikováno v: Frontiers in Neurology, Vol 13 (2022)

ImportanceMultiple sclerosis can also affect children. Approximately 3–10% of patients develop multiple sclerosis before the age of 16.ObjectiveThe aim of this analysis is to describe the characteristics of pediatric patients with multiple sclerosi

Externí odkaz: https://doaj.org/article/d9ce93a6892340cf87ef140dd44f18d7

Zobrazit plný text záznamu

Akademický článek

Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

Autor: Zbyšek Pavelek, Lukáš Sobíšek, Jana Šarláková, Pavel Potužník, Marek Peterka, Ivana Štětkárová, Pavel Štourač, Jan Mareš, Pavel Hradílek, Radek Ampapa, Markéta Grünermelová, Marta Vachová, Eva Recmanová, Francesco Angelucci, Simona Halúsková, Martin Vališ

Publikováno v: Frontiers in Neurology, Vol 11 (2021)

Background: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. Well-established drugs used for MS patients after the first demyelinating event in the Czech Republic include glatiramer acetat

Externí odkaz: https://doaj.org/article/d363f0282e7041f3a3b4674b61fb53d7

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání